{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-221863","form_type":"8-K","ticker":"INKT","cik":"0001840229","company_name":"MiNK Therapeutics, Inc.","filed_at":"2025-09-29T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.283664+00:00","generated_at":"2026-05-17T05:26:27.005972+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"MiNK Therapeutics appoints trauma expert Col. (Ret.) John Holcomb to Board","bullets":["Dr. John Holcomb elected as Class II director; term expires at 2026 annual meeting.","Option granted for 4,174 shares vesting over three years under 2021 Equity Plan.","Holcomb served 23 years in U.S. Army, pioneered combat casualty care; 780+ publications.","Appointment aims to advance iNKT therapies into immune-mediated disease and pulmonary disorders."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-221863","json":"https://secwatch.observer/filing/0001193125-25-221863.json","markdown":"https://secwatch.observer/filing/0001193125-25-221863.md","text":"https://secwatch.observer/filing/0001193125-25-221863.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840229/000119312525221863/0001193125-25-221863-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840229/000119312525221863/inkt-20250923.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T05:26:27.005972+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}